马蹄肾肿瘤手术的意义:结局与手术实践的对比研究
该研究基于梅奥诊所肾切除登记库1971至2021年数据,将34例马蹄肾(HSK)局限性可疑肾癌实体瘤患者与102例非融合非异位肾对照者按因素1:3匹配,比较30天并发症、估算肾小球滤过率变化及生存率。结果显示HSK组出血量和手术时间显著更高,但并发症率、肾功能变化及5年生存率与对照组无显著差异。
要点
- 马蹄肾组副肾动脉峡部动脉出现率为93%,其中43%存在多支动脉,7%有6支及以上动脉。
- 马蹄肾组估计失血量900 mL vs 对照组300 mL(P=.004),手术时间246分钟 vs 163分钟(P<.001)。
- 马蹄肾组5年总生存、癌特异生存、无转移生存分别为72%、91%、69%,与对照组79%、86%、77%相比无显著差异(P>.05)。
核心结论
- 马蹄肾肿瘤手术技术上具有挑战性且出血量更高,但在有经验的中心,其并发症和生存结局与非马蹄肾患者相当。
研究设计与样本
- 研究检查了梅奥诊所肾切除登记库1971年至2021年的实体瘤数据。
- 每例马蹄肾病例按多种因素与三例非马蹄肾患者匹配。
- 34例马蹄肾患者与102例非融合非异位肾对照患者纳入比较。
主要发现
- 马蹄肾组34例中30例为恶性肿瘤,非融合非异位肾对照组102例中90例为恶性肿瘤。
- 马蹄肾组副肾动脉峡部动脉出现率为93%,其中43%存在多支动脉,7%有6支及以上动脉。
- 马蹄肾组估计失血量900 mL vs 对照组300 mL(P=.004),手术时间246分钟 vs 163分钟(P<.001)。
- 马蹄肾组总体并发症率为26% vs 对照组17%(P=.2),3个月时估算肾小球滤过率中位变化为-8.5 vs 对照组-8.1(P=.8)。
- 5年随访时,马蹄肾组总生存、癌特异生存、无转移生存分别为72%、91%、69%,匹配对照组分别为79%、86%、77%(P>.05)。
临床怎么用
- 原文结论指出马蹄肾肿瘤手术技术上具有挑战性且出血量更高,但在有经验的中心其并发症和生存结局与非马蹄肾患者相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To contrast surgical outcomes of Horseshoe Kidney (HSK) patients with localized renal masses suspected of cancer with nonfused nonectopic kidney patients, emphasizing safe surgical practices for HSKs. METHODS: The study examined solid tumors from the Mayo Clinic Nephrectomy registry between 1971 and 2021. Each HSK case was matched to three non-HSK patients based on various factors. The outcomes measured included complications within 30days of surgery, change in estimated glomerular filtration rate, and overall, cancer-specific, and metastasis-free survival rates. RESULTS: Thirty of the 34 HSKs had malignant tumors compared with 90 of the 102 patients in the nonfused nonectopic referent cohort. Accessory isthmus arteries were present in 93% of HSK cases, with 43% exhibiting multiple arteries and 7% with 6 or more arteries. Estimated blood loss and surgery duration were significantly higher in HSKs (900 vs 300 mL, P = .004; 246 vs 163 minutes, P < .001, respectively). The HSK group demonstrated an overall complication rate of 26% (vs 17% in referents, P = .2) and a median change in estimated glomerular filtration rate at 3months of - 8.5 (vs -8.1 in referents, P = .8). At 5-year follow-up, survival rates for HSK patients were 72%, 91%, and 69% for overall, cancer-specific, and metastasis-free survival, respectively. The corresponding rates were 79%, 86%, and 77%, respectively, for matched referent patients (P > .05). CONCLUSION: HSK tumor management is technically challenging with higher blood loss; however, the data demonstrate comparable outcomes for patients with HSK tumors, including complications and survival, to those without HSKs in experienced centers.
引用
- Roshandel MR, Lohse CM, Sharma V, et al. Implications of Tumor Surgery in Horseshoe Kidneys: A Comparative Study of Outcomes and Surgical Practices. Urology. 2023. PMID: 37331487. doi:10.1016/j.urology.2023.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。